Nijhuis E W, vd Wiel-van Kemenade E, Figdor C G, van Lier R A
Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, University of Amsterdam.
Cancer Immunol Immunother. 1990;32(4):245-50. doi: 10.1007/BF01741708.
Cytotoxic T lymphocytes from healthy donors can be expanded to high numbers from the peripheral blood using combinations of anti-CD3 and anti-CD28 monoclonal antibodies (mAb). We investigated whether these antibodies could also be used to induce outgrowth of tumour-infiltrating lymphocytes (TIL) from tumour tissue. In the initiation phase of TIL culture immobilized anti-CD3 antibodies together with anti-CD28 mAb and low-dose interleukin-2 induced a rapid expansion of T cells from various human tumour tissues. The cultured cells showed high levels of cytotoxic T lymphocyte activity, but low levels of lymphokine-activated killer cell activity were generated. This study shows that TIL can be efficiently expanded from tumour tissue by combinations of anti-CD3 and anti-CD28 antibodies. This protocol for cell expansion in vitro may substantially reduce the time required to reach sufficient numbers of TIl for re-infusion to the patient.
使用抗CD3和抗CD28单克隆抗体（mAb）的组合，可以从健康供体的外周血中将细胞毒性T淋巴细胞大量扩增。我们研究了这些抗体是否也可用于诱导肿瘤组织中肿瘤浸润淋巴细胞（TIL）的生长。在TIL培养的起始阶段，固定化抗CD3抗体与抗CD28 mAb和低剂量白细胞介素-2一起诱导了来自各种人类肿瘤组织的T细胞快速扩增。培养的细胞显示出高水平的细胞毒性T淋巴细胞活性，但产生的淋巴因子激活的杀伤细胞活性水平较低。这项研究表明，通过抗CD3和抗CD28抗体的组合，可以有效地从肿瘤组织中扩增TIL。这种体外细胞扩增方案可能会大大减少达到足够数量的TIL以重新输注给患者所需的时间。
